Texas Yale Capital Corp. held its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent disclosure with the SEC. The fund owned 8,401 shares of the medical research company’s stock at the end of the first quarter. Texas Yale Capital Corp.’s holdings in Amgen were worth $1,378,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. increased its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. First Command Financial Services Inc. increased its stake in shares of Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock worth $254,000 after buying an additional 17 shares during the period. Cribstone Capital Management LLC increased its stake in shares of Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock worth $182,000 after buying an additional 25 shares during the period. Cable Hill Partners LLC increased its stake in shares of Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock worth $161,000 after buying an additional 26 shares during the period. Finally, Howe & Rusling Inc. increased its stake in shares of Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock worth $485,000 after buying an additional 31 shares during the period. 79.12% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (AMGN) traded down 0.31% during mid-day trading on Friday, hitting $167.29. The stock had a trading volume of 1,741,936 shares. The stock has a 50-day moving average price of $174.04 and a 200 day moving average price of $168.05. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21. The stock has a market cap of $122.07 billion, a P/E ratio of 15.24 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the firm earned $2.84 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts forecast that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.75%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.
COPYRIGHT VIOLATION WARNING: This article was first published by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/amgen-inc-nasdaqamgn-position-held-by-texas-yale-capital-corp-updated-updated-updated.html.
Several analysts have recently weighed in on the company. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target on the stock. in a research report on Friday, July 21st. They noted that the move was a valuation call. Jefferies Group LLC reiterated a “hold” rating and set a $180.00 target price on shares of Amgen in a research report on Monday, May 22nd. Leerink Swann reiterated a “market perform” rating and set a $161.00 target price on shares of Amgen in a research report on Thursday, June 22nd. Credit Suisse Group set a $177.00 target price on Amgen and gave the stock a “hold” rating in a research report on Friday, July 14th. Finally, UBS AG set a $180.00 target price on Amgen and gave the stock a “hold” rating in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. Amgen currently has an average rating of “Buy” and an average price target of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.20% of the stock is owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.